35 results about "HPV Antigen" patented technology

The current invention provides improved methods and means for the treatment of virally induced intraepithelial neoplasias of the ano-genital tract, such as HPV induced vulvar-, cervical-, vaginal-, penile- and anal intraepithelial neoplasias (VIN, CIN, VAIN, PIN and AIN). The invention provides a method of treatment of a subject suffering from an anogenital intraepithelial neoplasia comprising at least the steps of first determining whether the subject has a T-cell reactivity for viral early antigens, in particular high risk type HPV antigens; and subsequently a local treatment of the neoplasia with immune modulating compounds eliciting local inflammation if the subject scores positive for the T-cell reactivity, preferably a CD4+response against HPV early antigens. The invention also comprises methods and means to induce or further stimulate a cellular immune response against HPV antigens, prior to or during treatment with the immune modulating compound capable of eliciting a local inflammatory response.

The invention discloses a quick and accurate HPV (human papillomavirus) immunochromatographic detection test strip, a method for preparing the same and a HPV detection method on the basis of immunochromatographic technologies. The immunochromatographic technologies are applied to detecting HPV antigen protein for the first time, and accordingly the HPV immunochromatographic detection test strip has high-specificity and high-sensitivity detection performance. Compared with Pasteur and HPV-DNA (deoxyribonucleic acid) detection reported in existing literature, the HPV immunochromatographic detection test strip, the method and the HPV detection method have the main advantages that the HPV immunochromatographic detection test strip and the HPV detection method are short in detection time (5-20 minutes); optional special instruments can be omitted; the HPV immunochromatographic detection test strip is easy and convenient to operate and low in detection cost, only one-step reaction is required, and operators do not need to be trained; special temperature requirements and freezing can be omitted, and accordingly the HPV immunochromatographic detection test strip is convenient to store and transport and can be stored at the room temperatures for 24 months.

This document describes compositions and methods for inducing an immune response (e.g., a cellular response such as a cell-mediated cytolytic immune response) to a human papillomavirus (HPV) antigen, which can be displayed by HPV or exhibited by infected cells (e.g., cells from cervical and other tumors). The HPV protein can be joined to a stress protein by chemical conjugation or noncovalently using linking moieties, or by fusion (e.g., a recombinant fusion protein). Also described are expression vectors containing sequences encoding HPV antigens and stress proteins, which can be introduced into cells of a subject or cells ex vivo. Also described are compositions that include a stress protein linked to an HPV antigen and another pharmacologically acceptable component and stress protein—HPV antigen fusions and conjugates. These compositions can be used to induce or enhance an immune response against HPV and cells that exhibit HPV antigens, including HPV-associated tumors.

The invention discloses a method for preparing HPV (human papillomavirus) antigen specific CTL (cytotoxic T lymphocyte) and particularly discloses a preparation method of HLA-A2402 restrictive anti-HPV antigen specific CTL. According to the method, a peripheral blood mononuclear cell is collected through single blood collection or venous blood collection, the antigen presentation function of B cells is enhanced with CpG ODN 2395, the B cells supporting HLA-A2402 restrictive HPV antigen peptide are used for stimulating the peripheral blood mononuclear cell, rhIL-2, rhIL-7, rhIL-15 and rhIL-21 are jointly used to promote growth of the T cell. The target CTL prepared with the method has the characteristics that preparation is simple, the preparation cycle is short, the cost is low, the multiplication capacity and the killing activity are high, the cell viability is high and the like, and can be used for immunotherapy of HPV infection related diseases including cervical cancer.

The present application provides immune cells comprising an HPV antigen and an adjuvant, methods of manufacturing such modified immune cells, and methods of using such modified immune cells for treating an HPV-associated disease, preventing an HPV-associated disease and / or for modulating an immune response in an individual with an HPV-associated disease.

An immunity enhancing therapeutic vaccine includes a gene vector based on recombinant adenovirus and three elements: 1) an HPV antigen including the E6 and E7 multivalent fusion proteins of HPV types 16 and 18, 2) an immunologic adjuvant protein fused with said antigen, which protein may be a heat shock protein (HSP) of Mycobacterium tuberculosis, and 3) an immunostimulant, which may be granulocyte-macrophage colony stimulating factor (GM-CSF). The vaccine is used for the treatment of human papilloma virus infections and related diseases.

Safe, rapid, and efficient methods for producing antigen-specific T cells recognizing human papilloma virus (HPV antigens); HPV-specific T cells, and methods for treating HPV infections and HPV-related malignancies by adoptive transfer of HPV-specific T cells.

The present invention relates to combined vaccines against measles and human papilloma virus (HPV). In particular, the invention relates to recombinant measles virus vectors containing heterologous nucleic acid encoding single or several antigens derived from HPV, preferably, the major capside antigen L1, the minor capside antigen L2, the early gene E6 and the early gene E7 oncoproteins of HPV type 16, and optionally of types 18, 6 and 11. In a first embodiment, prophylactic vaccines are generated expressing HPV antigens, preferably L1 and / or L2 such that they induce a potent long-lasting immune response in mammals, preferably humans, to protect against HPV and MV infection. In another embodiment, therapeutic vaccines are generated expressing E6 and E7 proteins, and optionally L1 and L2, such that they induced strong immune responses will resolve persistent HPV infections at early or late stages, including HPV-induced cervical carcinoma. In a preferred embodiment, the combined vaccines are easy to produce on a large scale and can be distributed at low cost.

Disclosed are therapeutic compositions and methods for inducing an immune response to human papillomavirus (HPV). More particularly, disclosed is a method for inducing an immune response in a subject by introducing and expressing a nucleic acid molecule encoding an immunogenic HPV antigen.

Safe, rapid and efficient methods for producing antigen-specific T cells recognizing human papilloma virus or HPV antigens.

Safe, rapid and efficient methods for producing antigen-specific T cells recognizing human papilloma virus or HPV antigens.

The present application provides immune cells comprising an HPV antigen and an adjuvant, methods of manufacturing such modified immune cells, and methods of using such modified immune cells for treating an HPV-associated disease, preventing an HPV-associated disease and / or for modulating an immune response in an individual with an HPV-associated disease.

The invention discloses a preparation method of HLA-A0201-restricted anti-HPV (human papillomavirus) antigen-specific CTL. The preparation method comprises the following steps of: collecting peripheral blood mononuclear cells through apheresis, and enriching and purifying CD8+T lymphocytes; stimulating the CD8 + T lymphocytes by mature dendritic cells of a loaded HLA-A0201-restricted HPV antigen polypeptide; and promoting the T-cell growth through combined use of rhIL-2 and rhIL-7; purifying a target CTL by a Tetramer marking method and a flow cytometry sorting technique; stimulating the growth of the target CTL by solid phase packaged anti-human CD3 monoclonal antibody and IL-2; adding autologous PBMCs (peripheral blood mononuclear cell) after gamma-ray irradiation for enhancing activation of the target CTL; and adding rhIL-15, cultivating and amplifying, and collecting and identifying. The target CTL prepared by the prepared method has high purity, high proliferative capacity, high killing activity and a high CTL-CM ratio and can be applied to immunotherapy of tumors and the like.

A method for enhancing immunogenicity of an epitope peptide of an HPV antigen, the method including: assembling a gene of an HPV antigen into a gene of HBc, exogenously expressing a resulting assembled gene to acquire a fusion protein, allowing the fusion protein to automatically assemble to form a virus-like particle including the HPV antigen on a surface of the virus-like particle, to obtain HBc-HPV virus-like particle. A virus-like particle capable of expressing the antigen peptide of HPV acquired by the method. The virus-like particle includes a HBc-L2 fusion protein. A genome for encoding the HBc-L2 fusion protein is represented by SEQ ID NO. 3. A method for preparing an HPV vaccine includes using the virus-like particle.

The invention discloses a method for preparing HPV antigen-specific cytotoxic T lymphocytes. Specifically, the present invention discloses a preparation method of HLA-A2402-restricted anti-HPV antigen-specific CTL. In this method, peripheral blood mononuclear cells were collected by apheresis or venous blood sampling, the antigen presentation function of B cells was enhanced with CpG ODN 2395, and peripheral blood mononuclear cells were stimulated with B cells loaded with HLA-A2402-restricted HPV antigen peptides, and rhIL ‑2, rhIL‑7, rhIL‑15, rhIL‑21 combined to promote T cell growth. The target CTL prepared by the method has the characteristics of simple preparation, short preparation cycle, low cost, high proliferation ability, high killing activity, high cell viability and the like, and can be used for immunotherapy of diseases related to HPV infection including cervical cancer.

The invention provides an HPV (human papillomavirus) antigen epitope as well as an identification method and application thereof. The HPV antigen epitope comprises 1) 75-83 amino acids of HPV E7 protein; 2) 75-82 amino acids of the HPV E7 protein; 3) 77-86 amino acids of the HPV E7 protein; 4) 77-90 amino acids of the HPV E7 protein; 5) 79-88 amino acids of the HPV E7 protein; and 6) 4-11 amino acids of the HPV E7 protein. An HPV antigen epitope is obtained by utilizing an identification method of the screened and optimized HPV antigen epitope, the obtained HPV antigen epitope is applied, various dominant mutants are further obtained, drugs and vaccines prepared from the HPV antigen epitope or the mutants can effectively treat various cancers, and the HPV antigen epitope or the mutants are higher in safety and smaller in side effect.

Disclosed are therapeutic compositions and methods for inducing an immune response to human papillomavirus (HPV). More particularly, disclosed is a method for inducing an immune response in a subject by introducing and expressing a nucleic acid molecule encoding an immunogenic HPV antigen.

An immunity enhancing therapeutic vaccine includes a gene vector based on recombinant adenovirus and three elements: 1) an HPV antigen including the E6 and E7 multivalent fusion proteins of HPV types 16 and 18, 2) an immunologic adjuvant protein fused with said antigen, which protein may be a heat shock protein (HSP) of Mycobacterium tuberculosis, and 3) an immunostimulant, which may be granulocyte-macrophage colony stimulating factor (GM-CSF). The vaccine is used for the treatment of human papilloma virus infections and related diseases.